Compile Data Set for Download or QSAR
Report error Found 320 Enz. Inhib. hit(s) with all data for entry = 13197
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766209(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 0.0700nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766286(9-(4-hydroxybicyclo[2.2.2]octan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 0.710nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766268(8-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetSerine-protein kinase ATM(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766244(2-((5-fluoro-2-methyl-4-(oxazol-5-yl)phenyl)amino)...)
Affinity DataIC50: 1nMAssay Description:The assay detects kinase activity by antibody based HTRF assay. The GST-tagged p53 protein serves as substrate and Eu-labeled-antibody with specific ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766213(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766244(2-((5-fluoro-2-methyl-4-(oxazol-5-yl)phenyl)amino)...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766253(9-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)-7-methyl-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766267(8-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766254(9-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)-7-methyl-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766214(9-(4-methoxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766252(9-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)-7-methyl-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766266(8-(3-fluorobicyclo[1.1.1]pentan-1-yl)-5-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766211(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766281(7'-(3-fluorobicyclo[1.1.1]pentan-1-yl)-2'-((6-meth...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766212(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766272(8-(4-methoxybicyclo[2.2.1]heptan-1-yl)-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766217(9-(4-methoxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766257(N-(1-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-1H-pyraz...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766232(4-(7-methyl-2-((6-methylbenzo[d][1,3]dioxol-5-yl)a...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766218(9-(4-methoxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766258(N-(1-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-1H-pyraz...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766233(9-(4-methoxybicyclo[2.2.2]octan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766270(8-(4-methoxybicyclo[2.2.1]heptan-1-yl)-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766215(9-(4-methoxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766269(8-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766285(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-(methyl-d...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766216(9-(4-methoxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766276(7'-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-2'-((6-met...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766275(7'-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-2'-((7-met...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766274(7'-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-2'-((7-met...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766219(9-(3-fluorobicyclo[1.1.1]pentan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766234(9-(4-methoxybicyclo[2.2.2]octan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766220(9-(3-fluorobicyclo[1.1.1]pentan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766273(8-(4-methoxybicyclo[2.2.1]heptan-1-yl)-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766245(2-((5-fluoro-2-methyl-4-(1-methyl-1H-pyrazol-4-yl)...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766235(9-(4-hydroxybicyclo[2.2.2]octan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766210(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766280(7'-(3-fluorobicyclo[1.1.1]pentan-1-yl)-2'-((7-meth...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766250(9-((1s,4s)-bicyclo[2.2.2]octan-2-yl)-7-methyl-2-((...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766279(7'-(3-fluorobicyclo[1.1.1]pentan-1-yl)-2'-((7-meth...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766263(8-{4-Hydroxybicyclo[2.2.1]heptan-1-yl}-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766251(9-((1s,4s)-bicyclo[2.2.2]octan-2-yl)-7-methyl-2-((...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766278(7'-(3-fluorobicyclo[1.1.1]pentan-1-yl)-2'-((7-meth...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766222(9-(3-fluorobicyclo[1.1.1]pentan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766238(9-(4-methoxybicyclo[2.1.1]hexan-1-yl)-7-methyl-2-(...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766277(7'-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-2'-((6-met...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766261(8-{4-Hydroxybicyclo[2.2.1]heptan-1-yl}-5-methyl-2-...)
Affinity DataIC50: 1nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766284(7'-(3-fluorobicyclo[1.1.1]pentan-1-yl)-2'-((6-meth...)
Affinity DataIC50: 5.5nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetSerine-protein kinase ATM(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766228(9-(3-(methoxymethyl)bicyclo[1.1.1]pentan-1-yl)-7-m...)
Affinity DataIC50: 5.5nMAssay Description:The assay detects kinase activity by antibody based HTRF assay. The GST-tagged p53 protein serves as substrate and Eu-labeled-antibody with specific ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766228(9-(3-(methoxymethyl)bicyclo[1.1.1]pentan-1-yl)-7-m...)
Affinity DataIC50: 5.5nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

Displayed 1 to 50 (of 320 total ) | Next | Last >>
Jump to: